Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys

Daniel Navot; D Navot; Z Rosenwaks; Zev Rosenwaks; F Anderson; Freedolph D. Anderson; Gary D. Hodgen; G. D. Hodgen

doi:10.1016/s0015-0282(16)54354-4

Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys

Daniel Navot, D Navot, Z Rosenwaks, Zev Rosenwaks, F Anderson, Freedolph D. Anderson, Gary D. Hodgen, G. D. Hodgen

Fertility and sterility · 1991 · vol. 55(6) , pp. 1069–1075 · doi:10.1016/s0015-0282(16)54354-4 · PMID:1828042 · W2341905489

Other OA: closed CC0 ⤵ 1 in-corpus citation

View on OpenAlex View on PubMed View at publisher

⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This paper investigates the side effects of low-dose gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation in both women and monkeys.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To determine whether low (subtherapeutic) doses of gonadotropin-releasing hormone agonists (GnRH-a) can cause ovarian hyperstimulation. DESIGN: The study is in two parts: a preliminary clinical trial of women and a follow-up study in laboratory primates. SETTING: Normal human volunteers were studied in an academic research environment; primates were in a conventional laboratory setting. PATIENTS, PARTICIPANTS: Human volunteers were selected on the basis of apparent normal health. The monkeys were believed to be of normal reproductive status. INTERVENTIONS: Gonadotropin-releasing hormone agonists were administered at subtherapeutic doses. MAIN OUTCOME MEASURES: After observing ovarian hyperstimulation in two of five women receiving low doses of GnRH-a, a study was specifically designed to test the hypothesis that at low (subtherapeutic) doses of GnRH-a the "flare-effect" can be sustained without achieving down regulation. RESULTS: The data in women and monkeys suggest that a highly individualized response to low GnRH-a doses can be manifested as ovarian hyperstimulation. CONCLUSION: Four points of interpretation are offered: (1) that subtherapeutic doses of GnRH-a can cause ovarian hyperstimulation and related sequelae; (2) this may be a unique observation in that, typically, lower doses of medications have a lower incidence of negative side effects; (3) the findings suggest that GnRH-a prescribed in self-administration regimens may be more prone to such problems in noncompliant patients; and (4) the hyperstimulation response of the ovaries to low GnRH-a doses may indicate a new approach to controlled ovulation induction, although wide individualism was found.

My notes (saved in your browser only)

MeSH descriptors

Gonadotropin-Releasing Hormone Ovary Pituitary Gland Triptorelin Pamoate Triptorelin Pamoate Administration, Intranasal Adult Animals Delayed-Action Preparations Drug Administration Schedule Estradiol Estradiol Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Injections, Intramuscular Injections, Subcutaneous

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (24)

Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial via openalex
Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: an individualized, intermittent regimen via openalex
Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group via openalex
"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis via openalex
The value of in vitro fertilization for the treatment of unexplained infertility via openalex
Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin) via openalex
doi:10.1007/bf01135679 via openalex
doi:10.1016/0002-9378(85)90554-x via openalex
doi:10.1016/s0015-0282(16)60615-5 via openalex
doi:10.1007/978-94-009-5588-2_18 via openalex
doi:10.1210/jcem-52-2-370 via openalex
doi:10.1007/978-94-009-5588-2_19 via openalex
doi:10.1097/00006254-198905000-00001 via openalex
doi:10.1016/s0015-0282(16)60493-4 via openalex
W6603844359 via openalex
W6626684215 via openalex
doi:10.1016/s0015-0282(16)54018-7 via openalex
doi:10.1016/s0015-0282(16)60135-8 via openalex
doi:10.1016/s0015-0282(16)60121-8 via openalex
doi:10.1016/s0015-0282(16)60077-8 via openalex
doi:10.1016/s0015-0282(16)60486-7 via openalex
doi:10.1016/0010-7824(89)90064-4 via openalex
doi:10.1016/s0015-0282(16)59763-5 via openalex
doi:10.1016/s0039-128x(78)80012-9 via openalex

Cited by (1)

A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer 2005

Source provenance

openalex: last seen: 2026-05-14T06:19:26.718892+00:00
pubmed: last seen: 2026-10-08T21:05:01.267406+00:00

License: CC0 · commercial use OK

[1] Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial via openalex

[2] Gonadotropin-releasing hormone agonist suppresses ovulation, menses, and endometriosis in monkeys: an individualized, intermittent regimen via openalex

[3] Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group via openalex

[4] "Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis via openalex

[5] The value of in vitro fertilization for the treatment of unexplained infertility via openalex

[6] Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin) via openalex

[7] doi:10.1007/bf01135679 via openalex

[8] doi:10.1016/0002-9378(85)90554-x via openalex

[9] doi:10.1016/s0015-0282(16)60615-5 via openalex

[10] doi:10.1007/978-94-009-5588-2_18 via openalex

[11] doi:10.1210/jcem-52-2-370 via openalex

[12] doi:10.1007/978-94-009-5588-2_19 via openalex

[13] doi:10.1097/00006254-198905000-00001 via openalex

[14] doi:10.1016/s0015-0282(16)60493-4 via openalex

[15] W6603844359 via openalex

[16] W6626684215 via openalex

[17] doi:10.1016/s0015-0282(16)54018-7 via openalex

[18] doi:10.1016/s0015-0282(16)60135-8 via openalex

[19] doi:10.1016/s0015-0282(16)60121-8 via openalex

[20] doi:10.1016/s0015-0282(16)60077-8 via openalex

[21] doi:10.1016/s0015-0282(16)60486-7 via openalex

[22] doi:10.1016/0010-7824(89)90064-4 via openalex

[23] doi:10.1016/s0015-0282(16)59763-5 via openalex

[24] doi:10.1016/s0039-128x(78)80012-9 via openalex